On this page

Desoximetasone

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Desoximetasone
Generic name
Desoximetasone
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
15
Packages
33
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Desoximetasone .5 mg/g 1376338 View
Desoximetasone 2.5 mg/g 1376338 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
48

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
077770
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 20, 2015
Sponsor
PADAGIS ISRAEL
Products on application
1
Submissions recorded
1
Products approved under application 077770.
Product Trade name Form Strength Ingredient Status TE Flags
077770-001 DESOXIMETASONE OINTMENT DESOXIMETASONE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 077770.
Type No. Action Status Date Review
Original application 1 Approved April 20, 2015 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251125). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251125 HUMAN PRESCRIPTION DRUG · 20251002 HUMAN PRESCRIPTION DRUG · 20221004 HUMAN PRESCRIPTION DRUG · 20160601

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply a thin film of Desoximetasone Ointment USP, 0.05% to the affected skin areas twice daily. Rub in gently.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Desoximetasone Ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

WARNINGS Keep out of reach of children.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies the incidence of adverse reactions was low (0.2%) for Desoximetasone Ointment USP, 0.05% and included mild burning sensation at the site of application. To report SUSPECTED ADVERSE REACTIONS , contact The J. Molner Company LLC at 1-800-552-8750 and/or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Each gram of Desoximetasone Ointment USP, 0.25% contains 2.5 mg of desoximetasone in an ointment base consisting of fractionated coconut oil and white petrolatum. The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11b,16α)-. Desoximetasone has the molecular formula C 22 H 29 FO 4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The structural formula is: structured product formula for Desoximetasone

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Desoximetasone ointment USP, 0.05% is supplied as follows: 60 gram tubes: NDC 68180-948-04 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. ® The brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Manufactured for: Lupin Pharmaceuticals, Inc. Naples, FL 34108 United States Manufactured by: Lupin Limited Pithampur (M.P.) – 454 775 India December 2024 ID#: 277875 Image

Adverse event reports

Source: openFDA FAERS
18,942
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DESOXIMETASONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0472-0479-15 0472-0479 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0479-15) / 15 g in 1 TUBE November 21, 2016
0472-0479-60 0472-0479 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0479-60) / 60 g in 1 TUBE November 21, 2016
63629-8641-1 63629-8641 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8641-1) / 15 g in 1 TUBE May 14, 2015
63629-8642-1 63629-8642 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8642-1) / 60 g in 1 TUBE June 16, 2015
72162-1414-2 72162-1414 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1414-2) / 15 g in 1 TUBE August 17, 2023
72162-1414-6 72162-1414 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1414-6) / 60 g in 1 TUBE August 17, 2023
72162-2629-1 72162-2629 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2629-1) / 100 g in 1 TUBE April 23, 2026
72162-2629-6 72162-2629 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2629-6) / 60 g in 1 TUBE April 23, 2026
68462-531-17 68462-531 Glenmark Pharmaceuticals Inc., USA 15 g in 1 TUBE (68462-531-17) September 20, 2013
68462-531-65 68462-531 Glenmark Pharmaceuticals Inc., USA 60 g in 1 TUBE (68462-531-65) September 20, 2013
68180-946-01 68180-946 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-946-01) / 15 g in 1 TUBE May 10, 2017
68180-946-04 68180-946 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-946-04) / 60 g in 1 TUBE May 10, 2017
68180-948-04 68180-948 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-948-04) / 60 g in 1 TUBE April 25, 2017
40032-024-60 40032-024 Novel Laboratories, Inc. 1 TUBE in 1 CARTON (40032-024-60) / 60 g in 1 TUBE May 10, 2016
40032-024-61 40032-024 Novel Laboratories, Inc. 1 TUBE in 1 CARTON (40032-024-61) / 15 g in 1 TUBE May 10, 2016
45802-496-14 45802-496 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-496-14) / 15 g in 1 TUBE May 14, 2015
45802-496-96 45802-496 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-496-96) / 60 g in 1 TUBE June 16, 2015
51672-1262-1 51672-1262 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1262-1) / 15 g in 1 TUBE June 7, 1996
51672-1262-2 51672-1262 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1262-2) / 30 g in 1 TUBE June 7, 1996
51672-1262-3 51672-1262 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1262-3) / 60 g in 1 TUBE June 7, 1996
51672-1262-7 51672-1262 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1262-7) / 100 g in 1 TUBE June 7, 1996
51672-1352-1 51672-1352 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1352-1) / 15 g in 1 TUBE January 17, 1985
51672-1352-2 51672-1352 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1352-2) / 30 g in 1 TUBE January 17, 1985
51672-1352-3 51672-1352 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1352-3) / 60 g in 1 TUBE January 17, 1985
51672-1352-7 51672-1352 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1352-7) / 100 g in 1 TUBE January 17, 1985
83148-021-60 83148-021 The J. Molner Company LLC 1 TUBE in 1 CARTON (83148-021-60) / 60 g in 1 TUBE February 1, 2025
83148-021-99 83148-021 The J. Molner Company LLC 1 TUBE in 1 CARTON (83148-021-99) / 100 g in 1 TUBE May 1, 2025
72578-095-01 72578-095 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-095-01) / 15 g in 1 TUBE October 23, 2020
72578-095-02 72578-095 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-095-02) / 60 g in 1 TUBE October 23, 2020
72578-095-03 72578-095 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-095-03) / 100 g in 1 TUBE October 23, 2020
70771-1166-0 70771-1166 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1166-0) / 100 g in 1 TUBE December 5, 2017
70771-1166-1 70771-1166 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1166-1) / 15 g in 1 TUBE December 5, 2017
70771-1166-3 70771-1166 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1166-3) / 60 g in 1 TUBE December 5, 2017
0472-0479 0472-0479 Actavis Pharma, Inc. — November 21, 2016
63629-8641 63629-8641 Bryant Ranch Prepack — May 14, 2015
63629-8642 63629-8642 Bryant Ranch Prepack — May 14, 2015
72162-1414 72162-1414 Bryant Ranch Prepack — May 14, 2015
72162-2629 72162-2629 Bryant Ranch Prepack — February 1, 2025
68462-531 68462-531 Glenmark Pharmaceuticals Inc., USA — September 20, 2013
68180-946 68180-946 Lupin Pharmaceuticals, Inc. — May 10, 2017
68180-948 68180-948 Lupin Pharmaceuticals, Inc. — April 25, 2017
40032-024 40032-024 Novel Laboratories, Inc. — May 10, 2016
45802-496 45802-496 Padagis Israel Pharmaceuticals Ltd — May 14, 2015
51672-1262 51672-1262 Sun Pharmaceutical Industries, Inc. — June 7, 1996
51672-1352 51672-1352 Sun Pharmaceutical Industries, Inc. — January 17, 1985
83148-021 83148-021 The J. Molner Company LLC — February 1, 2025
72578-095 72578-095 Viona Pharmaceuticals Inc — October 23, 2020
70771-1166 70771-1166 Zydus Lifesciences Limited — December 5, 2017

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.